Vimarsana
Biggest News Aggregation in the World

Page 2 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis - Vimarsana News

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years Safety was consistent with prior findings and the established safety...

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris - Vimarsana News

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatmentMonash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP; SXTPW), specialists in developing and marketing medicines for infectiou

Source: yahoo.com
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer - Vimarsana News

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

To lead U.S. commercial relaunch of ARAKODA® for malaria preventionWill support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON,...

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology® - Vimarsana News

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code - - Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect...

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (A - Vimarsana News

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (A

- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code -- Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable safety profile -NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC) today announced that...